文献速递核素与放射性配体治疗肿瘤 PET/CT

定量SPECT/CT指标在胃肠胰神经内分泌肿瘤患者[177Lu]Lu-DOTATATE治疗反应早期预测中的价值

Quantitative SPECT/CT Metrics in Early Prediction of [177Lu]Lu-DOTATATE Treatment Response in Gastroenteropancreatic Neuroendocrine Tumor Patients.
PubMed 文献 · J Nucl Med · 2024-10-01

该回顾性研究纳入27例接受4个周期[177Lu]Lu-DOTATATE治疗的不可切除或转移性、进展性、高分化、受体阳性的胃肠胰神经内分泌肿瘤患者,利用治疗周期末SPECT/CT计算肿瘤负荷评分变化(ΔTBS)和归一化峰值计数变化(ΔnPC),发现ΔTBS和ΔnPC可在第二个治疗周期预测治疗反应。

要点

  • ΔTBS在第二至第一周期即显示组间显著差异,PD组0.043 vs 非PD组-0.049(P=0.023)。
  • ΔTBS第四至第一周期AUC达0.957,灵敏度100%、特异度80%。
  • ΔnPC第二至第一周期组间差异显著(均值-0.107 vs -0.282,P=0.033),第三、四周期未达统计学显著。

核心结论

  • ΔTBS和ΔnPC可在第二个治疗周期预测[177Lu]Lu-DOTATATE治疗反应。

研究设计与样本

  • 回顾性纳入27例不可切除或转移性、进展性、高分化、受体阳性的胃肠胰神经内分泌肿瘤患者,均接受4个周期[177Lu]Lu-DOTATATE治疗。

主要发现

  • PD组7例,非PD组20例;ΔTBS第二至第一、第三至第一、第四至第一周期中位数分别为0.043 vs -0.049、0.08 vs -0.116、0.109 vs -0.123(P分别为0.023、0.002、<0.001)。
  • ΔnPC第二至第一周期均值-0.107 vs -0.282(P=0.033);第三至第一和第四至第一周期均值分别为-0.122 vs -0.312和-0.183 vs -0.405(P分别为0.117和0.067),未达统计学显著。
  • ΔTBS第四至第一周期AUC为0.957,灵敏度100%、特异度80%;第二至第一和第三至第一周期AUC分别为0.793和0.893,灵敏度均为71.4%,特异度分别为85%和95%。
  • ΔnPC第二至第一、第三至第一、第四至第一周期AUC分别为0.764、0.693、0.679;灵敏度分别为71.4%、71.4%、100%;特异度分别为75%、70%、35%。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Our objective is to explore quantitative imaging markers for early prediction of treatment response in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs) undergoing [177Lu]Lu-DOTATATE therapy. By doing so, we aim to enable timely switching to more effective therapies in order to prevent time-resource waste and minimize toxicities. Methods: Patients diagnosed with unresectable or metastatic, progressive, well-differentiated, receptor-positive GEP-NETs who received 4 sessions of [177Lu]Lu-DOTATATE were retrospectively selected. Using SPECT/CT images taken at the end of treatment sessions, we counted all visible tumors and measured their largest diameters to calculate the tumor burden score (TBS). Up to 4 target lesions were selected and semiautomatically segmented. Target lesion peak counts and spleen peak counts were measured, and normalized peak counts were calculated. Changes in TBS (ΔTBS) and changes in normalized peak count (ΔnPC) throughout treatment sessions in relation to the first treatment session were calculated. Treatment responses were evaluated using third-month CT and were binarized as progressive disease (PD) or non-PD. Results: Twenty-seven patients were included (7 PD, 20 non-PD). Significant differences were observed in ΔTBSsecond-first, ΔTBSthird-first, and ΔTBSfourth-first (where second-first, third-first, and fourth-first denote scan number between the second and first, third and first, and fourth and first [177Lu]Lu-DOTATATE treatment cycles), respectively) between the PD and non-PD groups (median, 0.043 vs. -0.049, 0.08 vs. -0.116, and 0.109 vs. -0.123 [P = 0.023, P = 0.002, and P < 0.001], respectively). ΔnPCsecond-first showed significant group differences (mean, -0.107 vs. -0.282; P = 0.033); ΔnPCthird-first and ΔnPCfourth-first did not reach statistical significance (mean, -0.122 vs. -0.312 and -0.183 vs. -0.405 [P = 0.117 and 0.067], respectively). At the optimal threshold, ΔTBSfourth-first exhibited an area under the curve (AUC) of 0.957, achieving 100% sensitivity and 80% specificity. ΔTBSsecond-first and ΔTBSthird-first reached AUCs of 0.793 and 0.893, sensitivities of 71.4%, and specificities of 85% and 95%, respectively. ΔnPCsecond-first, ΔnPCthird-first, and ΔnPCfourth-first showed AUCs of 0.764, 0.693, and 0.679; sensitivities of 71.4%, 71.4%, and 100%; and specificities of 75%, 70%, and 35%, respectively. Conclusion: ΔTBS and ΔnPC can predict [177Lu]Lu-DOTATATE response by the second treatment session.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Tuncer O, Steinberger D, Steiner J, et al. Quantitative SPECT/CT Metrics in Early Prediction of [177Lu]Lu-DOTATATE Treatment Response in Gastroenteropancreatic Neuroendocrine Tumor Patients. J Nucl Med. 2024. PMID: 39266296. doi:10.2967/jnumed.124.267964

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。